Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2018

Open Access 01-03-2018 | Review Article

Efficacy and Safety of Tiotropium in Children and Adolescents

Authors: Eckard Hamelmann, Stanley J. Szefler

Published in: Drugs | Issue 3/2018

Login to get access

Abstract

Asthma is one of the most common chronic diseases in children, with a high proportion of patients demonstrating poor control despite the availability of disease management guidelines. Global Initiative for Asthma guidelines include tiotropium as an add-on therapy option at Steps 4 and 5 in patients aged ≥ 12 years with a history of exacerbations, and tiotropium delivered via the Respimat® Soft Mist™ Inhaler has recently been approved for use as once-daily maintenance therapy for children with asthma over the age of 6 years in the USA. A large clinical trial program has been conducted in children, adolescents, and adults across the spectrum of asthma severity. Findings from these clinical studies and pooled analyses in children and adolescents with symptomatic moderate or severe asthma have demonstrated that tiotropium Respimat® as add-on to inhaled corticosteroids, with or without other maintenance therapies, is a well-tolerated and efficacious bronchodilator, showing improved lung function and trends towards improved asthma control, mirroring findings in adult studies. This review discusses the evidence to date for tiotropium Respimat® for the management of asthma in adolescents and children with symptomatic moderate and severe asthma, and considers the challenges of asthma management in these patients. Factors affecting this population group, such as poor adherence, underreporting of symptoms, and social and psychological issues, are highlighted, along with the need for active review and management of treatment to help achieve optimal control.
Literature
1.
2.
3.
Schmier JK, Manjunath R, Halpern MT, Jones ML, Thompson K, Diette GB. The impact of inadequately controlled asthma in urban children on quality of life and productivity. Ann Allergy Asthma Immunol. 2007;98:245–51.CrossRefPubMed
4.
5.
Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68:1520–31.CrossRefPubMed
6.
Belgrave DC, Buchan I, Bishop C, Lowe L, Simpson A, Custovic A. Trajectories of lung function during childhood. Am J Respir Crit Care Med. 2014;189:1101–9.CrossRefPubMedPubMedCentral
7.
Rodrigo GJ, Neffen H. A systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148:397–407.CrossRefPubMed
8.
Cazzola M, Ora J, Rogliani P, Matera MG. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017;11:239–53.CrossRefPubMed
9.
Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013;(8):CD000060.
10.
Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60:740–6.CrossRefPubMedPubMedCentral
11.
Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol (1985). 2006;101:971–85.CrossRef
12.
Vogelberg C. Emerging role of long-acting anticholinergics in children with asthma. Curr Opin Pulm Med. 2016;22:74–9.CrossRefPubMed
13.
Hashimoto A, Maeda H, Yokoyama M. Augmentation of parasympathetic nerve function in patients with extrinsic bronchial asthma: evaluation by coefficiency of variance of R-R interval with modified long-term ECG monitoring system. Kobe J Med Sci. 1996;42:347–59.PubMed
14.
Novelli F, Malagrino L, Dente FL, Paggiaro P. Efficacy of anticholinergic drugs in asthma. Expert Rev Respir Med. 2012;6:309–19.CrossRefPubMed
15.
16.
17.
Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64:457–64.CrossRefPubMed
18.
Haddad EB, Mak JC, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol. 1994;45:899–907.PubMed
19.
Meurs H, Oenema TA, Kistemaker LE, Gosens R. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol. 2013;13:316–23.CrossRefPubMed
20.
Radovanovic D, Santus P, Blasi F, Mantero M. The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med. 2017;12:17.CrossRefPubMedPubMedCentral
21.
Halpin DM, Kaplan AG, Russell RK. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respir Med. 2017;128:28–41.CrossRefPubMed
22.
Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30:653–61.CrossRefPubMed
23.
Ohta S, Oda N, Yokoe T, Tanaka A, Yamamoto Y, Watanabe Y, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010;40:1266–75.CrossRefPubMed
24.
25.
Novelli F, Costa F, Latorre M, Malagrino L, Celi A, Vagaggini B, et al. Tiotropium: a new therapeutic option in asthma. Monaldi Arch Chest Dis. 2013;79:109–15.CrossRefPubMed
26.
Paggiaro P, Halpin DM, Buhl R, Engel M, Zubek VB, Blahova Z, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4:104–13.CrossRefPubMed
27.
Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3:367–76.CrossRefPubMed
28.
Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, et al. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study. PLoS One. 2015;10:e0124109.CrossRefPubMedPubMedCentral
29.
Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–207.CrossRefPubMed
30.
Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HA, Zaremba-Pechmann L, et al. Safety and tolerability of once-daily tiotropium Respimat® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med. 2016;118:102–11.CrossRefPubMed
31.
Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med. 2014;108:1268–76.CrossRefPubMed
32.
Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16:20.CrossRefPubMedPubMedCentral
33.
Hamelmann E, Bateman ED, Vogelberg C, Szefler SJ, Vandewalker M, Moroni-Zentgraf P, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol. 2016;138:441–50.CrossRefPubMed
34.
Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1):1601100.CrossRefPubMedPubMedCentral
35.
Schmidt O, Hamelmann E, Vogelberg C, Laki I, El Azzi G, Engel M, et al. Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma. Eur Respir J. 2016;48 (Suppl. 60):PA4398.
36.
Szefler SJ, Murphy K, Harper T, Boner A, Laki I, Engel M, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;140:1277–87.CrossRefPubMed
37.
Vrijlandt E, El Azzi G, El Azzi G, Vandewalker M, Rupp N, Harper T, et al. Safety and efficacy of tiotropium in 1–5-year-old children with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018. (in press).
38.
Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate to severe symptomatic asthma: a systematic review. Pediatr Allergy Immunol. 2017;26:551–6.CrossRef
39.
Rodrigo GJ, Castro-Rodriguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2015;115:211–6.CrossRefPubMed
40.
Vogelberg C, Laki I, Schmidt O, Hamelmann E, El Azzi G, Engel M, et al. Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma. Eur Respir J. 2016;48 (Suppl. 60):PA4399.
41.
Vogelberg C, Hamelmann E, Szefler S, El Azzi G, Moroni-Zentgraf P, Engel M, et al. Once-daily tiotropium Respimat add-on therapy improves lung function and control in adolescents and children with moderate symptomatic asthma. J Allergy Clin Immunol. 2017;139(2):AB95.CrossRef
42.
Vandewalker M, Hamelmann E, Engel M, El Azzi G, Moroni-Zentgraf P, Unseld A, et al. Once daily tiotropium Respimat add-on therapy has a safety profile comparable with placebo in children and adolescents. J Allergy Clin Immunol. 2017;139(2):AB94.CrossRef
43.
Hamelmann E, Vogelberg C, Goldstein S, El Azzi G, Engel M, Sigmund R, et al. Once-daily tiotropium Respimat add-on therapy improves lung function in patients aged 6–17 years with severe symptomatic asthma. Pediatr Pulmonol. 2017;52(S46):S100–S176.
44.
Vogelberg C, Hamelmann E, Vrijlandt E, Engel M, El Azzi G, Moroni-Zentgraf P, et al. Tiotropium add-on therapy has a safety profile comparable with that of placebo in children and adolescents with symptomatic asthma. Allergy. 2017;72(S103):414.
45.
Morton RW, Everard ML, Elphick HE. Adherence in childhood asthma: the elephant in the room. Arch Dis Child. 2014;99:949–53.CrossRefPubMed
46.
Boonsawat W, Goryachkina L, Jacques L, Frith L. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma: a placebo-controlled comparison. Clin Drug Investig. 2008;28:101–11.CrossRefPubMed
47.
Diette GB, Markson L, Skinner EA, Nguyen TT, Algatt-Bergstrom P, Wu AW. Nocturnal asthma in children affects school attendance, school performance, and parents’ work attendance. Arch Pediatr Adolesc Med. 2000;154:923–8.CrossRefPubMed
48.
49.
Gustafsson D, Olofsson N, Andersson F, Lindberg B, Schollin J. Intervention models on psycho-social health in families with an asthmatic child. Pediatr Allergy Immunol. 2000;11:241–5.CrossRefPubMed
50.
Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206.CrossRefPubMed
51.
Hamelmann E, Vogelberg C, Voelker B, El Azzi G, Engel M, Sigmund R, Szefler SJ. Tiotropium add-on therapy improves lung function in children and adolescents with moderate and severe symptomatic asthma, independent of markers of allergic status. Allergy. 2017;72:S103.
52.
Vogelberg C, Halpin D, Voelker B, Engel M, Luehmann, Hamelmann E. Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction. Eur Respir J. 2017;50:4040.
53.
Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013;132:1068–74.e1.
54.
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–44.CrossRefPubMed
55.
McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med. 2016;374:1842–52.CrossRefPubMedPubMedCentral
56.
Wu AC, Gregory M, Kymes S, Lambert D, Edler J, Stwalley D, et al. Modeling asthma exacerbations through lung function in children. J Allergy Clin Immunol. 2012;130:1065–70.CrossRefPubMedPubMedCentral
57.
Fuhlbrigge AL, Kitch BT, Paltiel AD, Kuntz KM, Neumann PJ, Dockery DW, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol. 2001;107:61–7.CrossRefPubMed
58.
Teach SJ, Gergen PJ, Szefler SJ, Mitchell HE, Calatroni A, Wildfire J, et al. Seasonal risk factors for asthma exacerbations among inner-city children. J Allergy Clin Immunol. 2015;135:146–73.e5.
59.
60.
de Benedictis D, Bush A. Asthma in adolescence: is there any news? Pediatr Pulmonol. 2017;52:129–38.CrossRefPubMed
61.
Schaefer MR, Kavookjian J. The impact of motivational interviewing on adherence and symptom severity in adolescents and young adults with chronic illness: a systematic review. Patient Educ Couns. 2017;100(12):2190–9.CrossRefPubMed
62.
Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2002;(1):CD001117.
63.
Campbell JD, Brooks M, Hosokawa P, Robinson J, Song L, Krieger J. Community health worker home visits for Medicaid-enrolled children with asthma: effects on asthma outcomes and costs. Am J Public Health. 2015;105:2366–72.CrossRefPubMedPubMedCentral
64.
Partridge MR, Caress AL, Brown C, Hennings J, Luker K, Woodcock A, et al. Can lay people deliver asthma self-management education as effectively as primary care based practice nurses? Thorax. 2008;63:778–83.CrossRefPubMed
65.
66.
Navaratnam P, Friedman HS, Urdaneta E. The impact of adherence and disease control on resource use and charges in patients with mild asthma managed on inhaled corticosteroid agents. Patient Prefer Adherence. 2010;4:197–205.PubMedPubMedCentral
67.
De Simoni A, Horne R, Fleming L, Bush A, Griffiths C. What do adolescents with asthma really think about adherence to inhalers? Insights from a qualitative analysis of a UK online forum. BMJ Open. 2017;7:e015245.PubMedPubMedCentral
68.
Kamin W, Frank M, Kattenbeck S, Moroni-Zentgraf P, Wachtel H, Zielen S. A handling study to assess use of the Respimat® Soft Mist™ Inhaler in children under 5 years old. J Aerosol Med Pulm Drug Deliv. 2015;28:372–81.CrossRefPubMedPubMedCentral
69.
Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004;283:1–9.CrossRefPubMed
70.
Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–55.PubMedPubMedCentral
71.
Anderson WC 3rd, Szefler SJ. New and future strategies to improve asthma control in children. J Allergy Clin Immunol. 2015;136:848–59.CrossRefPubMed
72.
Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;208:317–41.CrossRef
73.
Barnes P. Muscarinic receptor subtypes in airways. Eur Respir J. 1993;6:328–31.PubMed
Metadata
Title
Efficacy and Safety of Tiotropium in Children and Adolescents
Authors
Eckard Hamelmann
Stanley J. Szefler
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0862-1

Other articles of this Issue 3/2018

Drugs 3/2018 Go to the issue

Adis Drug Evaluation

Eculizumab: A Review in Generalized Myasthenia Gravis

Adis Drug Evaluation

Landiolol: A Review in Tachyarrhythmias

Current Opinion

Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol

Correction

Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma

AdisInsight Report

Netarsudil Ophthalmic Solution 0.02%: First Global Approval

Review Article

Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults